Our founders’ insights and achievements
CriteriaCaixa reboosts its investment business in science and technology -based startups
Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer
08 Jan 2026: AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
08 Jan 2026: NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s
27 Oct 2025: Adaptam Therapeutics raises €3 million to pioneer cancer immunotherapies against immunosuppressive myeloid cells
08 Sep 2025: NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
23 Jul 2025: Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency
17 Jul 2025: Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases
07 May 2025: AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
29 Oct 2024: MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System
15 Oct 2024: Tolerance Bio, Inc. launches with $17.2 million in seed financing to advance thymus-based therapies for immune-mediated diseases
Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland
Criteria Bio Ventures leads €27 Mn round in AbolerIS Pharma to advance therapies against autoimmune diseases
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
Positive results from AELIX’ HIV therapeutic vaccine clinical study AELIX-002 published in Nature Medicine
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of €205M
Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
Caixa Capital Risc is leading the largest operation in the biotech sector in Spain, with a €55 million financing round in Sanifit
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure
NuMat Medtech secures a €530,000 round of investment
Minoryx Therapeutics raises €21.3M in Series B funding round
QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company
MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros
Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102
Stat Diagnostica announces 25 Million Euros in Series C Financing
”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital
Minoryx Therapeutics appoints Dr. Khalid Islam as chairman of the board of directors
Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine
PlantResponse Biotech raises 5.7 Million € in Series A funding
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)
Sanifit raises €36.6M ($41.3M) in Series C financing round
”la Caixa” leads a 1.6 million Euro round in Minoryx
"la Caixa" leads 3.6 million euro financing round in Sanifit
nLife Therapeutics recibe 350.000 dólares americanos de la Fundación Michael J. Fox para la investigación de la enfermedad de Parkinson
”la Caixa” and CRB Inverbío invest three million Euros in Nuubo, specialised in wearable technologies with medical applications
Laboratoris Sanifit begins the fight against calciphylaxis
Minoryx takes a step forward in the treatment of rare diseases
STAT-Diagnostica closes a 17 million euro financing round and brings in leading international investors
"la Caixa" and Inveready invest in Minoryx
MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding